Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 12/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | CCR1 | P32246 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30168445 | 1.00 | MBOAT4 (0.43) | MBOAT4LPAR1CYP3A4CCR1RAB9A | |
| SCHEMBL1840667 | 0.82 | MEN1 (0.36) | MBOAT4CCR1RAB9ACCR5CCR8 | |
| SCHEMBL21585390 | 0.80 | LPAR1 (0.36) | LPAR1CYP3A4CCR1RAB9ACCR5 | |
| SCHEMBL19837306 | 0.78 | MBOAT4 (0.39) | MBOAT4TRPV4 | |
| SCHEMBL29210904 | 0.77 | MBOAT4 (0.38) | MBOAT4TRPV4 | |
| SCHEMBL30271311 | 0.77 | MBOAT4 (0.38) | MBOAT4TRPV4 | |
| SCHEMBL19837520 | 0.77 | MBOAT4 (0.43) | MBOAT4TRPV4 | |
| SCHEMBL19844889 | 0.77 | MBOAT4 (0.38) | MBOAT4TRPV4 | |
| SCHEMBL21582555 | 0.77 | LPAR1 (0.34) | MBOAT4LPAR1CYP3A4CCR1RAB9A | |
| SCHEMBL29813506 | 0.77 | LPAR1 (0.34) | MBOAT4LPAR1CYP3A4CCR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | CONTINEUM THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4415706-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023014907-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023014907-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-11479546-B2 | Antimalarial hexahydropyrimidine analogues | UCB Biopharma SRL | 2022-10-25 | — | — | US | disclosed |
| EP-3774741-B1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-08 | — | — | EP | disclosed |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | UCB Biopharma SRL (BE) | 2021-04-01 | — | — | US | disclosed |
| EP-3494120-B1 | OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-17 | — | — | EP | disclosed |
| CN-111936472-A | Anti-malarial hexahydropyrimidine analogues | UCB生物制药有限责任公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2018024653-A1 | OXADIAZOLOPYRIDINE DERIVATES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | MBOAT4 449/4885LPAR1 1069/4885CYP3A4 4293/4885 |
| US-11479546-B2 | Antimalarial hexahydropyrimidine analogues | G6PD, DPYD, DHODH | MBOAT4 4305/4885LPAR1 2993/4885CYP3A4 174/4885 |
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | MBOAT4 315/4885LPAR1 1/4885CYP3A4 4412/4885 |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | G6PD, DPYD, DHODH | MBOAT4 4305/4885LPAR1 2993/4885CYP3A4 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.